Peter Golden
Child & Adolescent Psychiatry · Akron, OHNPI 1588867626
Payments from drug & device makers
Across 1,225 payments — averaging $16.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$3K
- AbbVie$2K
- Alkermes, Inc.$2K
- Johnson & Johnson$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
- Lundbeck LLC$1K
- plus $9K from 24 others
What the payments were for
- Food & beverage$20,18898%
- Education$4032%
- Gifts$10%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 160 | $3,038 |
| AbbVie(2 entities) | 119 | $1,797 |
| Alkermes, Inc. | 74 | $1,768 |
| Johnson & Johnson | 76 | $1,712 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 107 | $1,635 |
| Lundbeck LLC | 93 | $1,422 |
| Supernus Pharmaceuticals, Inc. | 129 | $1,032 |
| Neurocrine Biosciences, Inc. | 61 | $967 |
| Teva Pharmaceuticals USA, Inc. | 29 | $961 |
| E.r. Squibb & Sons, L.L.C. | 40 | $924 |
| Takeda Pharmaceuticals U.S.A., Inc. | 57 | $895 |
| Sunovion Pharmaceuticals Inc. | 51 | $820 |
| Corium, LLC | 47 | $698 |
| Axsome Therapeutics, Inc. | 34 | $665 |
| Vanda Pharmaceuticals Inc. | 25 | $549 |
| Ironshore Pharmaceuticals Inc. | 34 | $422 |
| Shire North American Group Inc | 16 | $268 |
| Indivior Inc. | 14 | $261 |
| Noven Therapeutics, LLC | 10 | $187 |
| Collegium Pharmaceutical, Inc. | 22 | $184 |
| Bausch Health US, LLC | 5 | $67 |
| Idorsia Pharmaceuticals US Inc | 4 | $67 |
| Luye Pharma (USA) Ltd. | 3 | $65 |
| Sage Therapeutics, LLC | 3 | $54 |
| Eisai Inc. | 2 | $41 |
| Tempus AI, Inc | 2 | $39 |
| Neuronetics, Inc. | 3 | $35 |
| Neos Therapeutics, LP | 1 | $13 |
| TMS Neurohealth Centers Inc. | 1 | $4 |
| Validus Pharmaceuticals LLC | 3 | $1 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$1,413
- ARISTADA$500
- INVEGA SUSTENNA$363
- COBENFY$356
- REXULTI$243
- INGREZZA$236
- INVEGA TRINZA$230
- VRAYLAR$128
- ARISTADA INITIO$125
- AUSTEDO$125
- ABILIFY MAINTENA$121
- UZEDY$106
- TRINTELLIX$103
How this compares
$20,593 in reported general payments places this provider in the 90th percentile of 160 child & adolescent psychiatry providers in Ohio.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 20 | $62,167 |
| LybalviOlanzapine/Samidorphan Malate | 36 | $54,473 |
| Abilify MaintenaAripiprazole | 19 | $53,290 |
| TrintellixVortioxetine Hydrobromide | 18 | $11,710 |
| Paliperidone ErPaliperidone | 13 | $7,616 |
| Atomoxetine Hcl | 16 | $3,509 |
| Fluoxetine Hcl | 15 | $1,700 |
| Trazodone Hcl | 21 | $849 |
| Haloperidol Decanoate | 13 | $679 |
| Hydroxyzine Hcl | 14 | $664 |
| Divalproex Sodium ErDivalproex Sodium | 19 | $520 |
| Guanfacine Hcl | 12 | $338 |
| Ziprasidone Hcl | 12 | $316 |
| Buspirone Hcl | 23 | $303 |
| Quetiapine Fumarate | 13 | $262 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna | $1,712 | $62,16720 claims |
| Alkermes, Inc.Lybalvi | $1,768 | $54,47336 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $3,038 | $53,29019 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $895 | $11,71018 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 160 child & adolescent psychiatry providers in Ohio.
Other child & adolescent psychiatry in Akron
- Jess LevyAkron$1K
- Jonathan PentzAkron$857
- Melissa DelbelloCincinnati$4.5M
- Luis Patino DuranCincinnati$652K
- Nora McNamaraCleveland$567K
- Robert FindlingCleveland$421K
- Craig EricksonCincinnati$275K
- Ernest PedapatiCincinnati$257K
- Lawrence ArnoldColumbus$215K
- Rick BowersMoraine$182K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.